The result of adjuvant Vinorelbine plus Cisplatin in completely resected stage IB-IIIA non-small cell lung cancer at Hanoi Medical Unoversity Hospital
Background: Assess clinical, subclinical characteristics of stage IB-IIIA non - small cell lung cancer patients (NSCLC). Evaluating the result of adjuvant vinorelbine plus cisplatin in completely resected stage IB - IIIA NSCLC. Methods: Descriptive study of 70 patients completely resected stage IB - IIIA non - small cell lung cancer were received adjuvant vinorelbine plus cisplatin chemotherapy at Hanoi Medical University Hospital from 01/2016 to 6/2020. Results: The mean age of 56.94 years old, male: female ratio was 2.9:1. 23 (32.8%) patients had postoperative stage IB disease, 24 (34.3%) had stage IIA disease, 13 (18.6%) had stage IIB disease and 10 (14.3%) had stage IIIA disease. The major histological type was adenocarcinoma (78.6%). Median disease free survival was 29.10 ± 1.63 months, and 3 - year survival was 41%. Chemotherapy caused hematologic side effects in 66.67% of patients including neutropenia in 61.4% and grade 3/4 neutropenia in 28.1%. Non - hematologic toxic effects of chemotherapy were reported at low rates and almost mild (grade 1/2). Conclusions: The vinorelbine - cisplatin regimen is an effective regimen in the adjuvant treatment of non - small cell lung cancer, the study showed that the results in disease - free survival and overall survival were comparable to those of other studies in the world. The most common side effect was neutropenia, the other side effects were reported at low rate and usually mild.